NCT04522817View on ClinicalTrials.gov

CLBS119 for Repair of COVID-19 Induced Pulmonary Damage

PHASE1WithdrawnINTERVENTIONAL
0
Timeline

Start Date

October 5, 2020

Primary Completion Date

May 31, 2021

Study Completion Date

May 31, 2021

Conditions
Covid-19
Interventions
BIOLOGICAL

CLBS119

Peripheral blood derived autologous CD34+ cells

Trial Locations (1)

10016

NYU Langone Health, New York

Sponsors
All Listed Sponsors
lead

Lisata Therapeutics, Inc.

INDUSTRY

NCT04522817 - CLBS119 for Repair of COVID-19 Induced Pulmonary Damage | Biotech Hunter | Biotech Hunter